These results support that activated STAT5 may continue to repress xCT expression in vivo, and that the changes in clonally selected, treatment-resistant cancer cells are likely not transient, given that tumours were allowed to grow for 25 days post-injection in the absence of SH-4-54 prior to sacrifice and tissue collection. The gene discussed is STAT5A; the disease is cancer.